News &

Media Contact

Amy Merves
Manager of
Media Relations



Fox Chase Cancer Center Study Shows Men Whose Prostate Cancers Occur Following Transurethral Resection Should Be Treated as High-Risk Patients if PSA Level Is in Intermediate Range

DENVER -- Researchers at Fox Chase Cancer Center recommend more aggressive treatment for men whose prostate cancers occurred after transurethral resection of the prostate (TURP) and whose PSA level is considered intermediate. A study supporting this recommendation was presented today at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Denver, Colo.

When planning for treatment, radiation oncologists evaluate the pretreatment PSA (prostate specific antigen) because it is a strong predictor of the patient's outcome following radiotherapy. The pretreatment PSA is used to determine the appropriate radiotherapy dose and whether androgen deprivation therapy should be given. Doctors say evaluating a patient's PSA level after surgical removal of some prostate tissue with a TURP, which is often done for men who have an enlarged prostate with significant urinary symptoms unrelated to prostate cancer, is not an accurate picture of disease progression.

"PSA is secreted from both normal and cancerous tissue," explained lead author David J. D'Ambrosio, M.D., a resident in the radiation oncology department at Fox Chase Cancer Center. "Patients who have had a TURP prior to their prostate cancer treatment may have lower pretreatment PSA levels because there is less prostate tissue remaining. This can mislead physicians regarding the extent of disease."

D'Ambrosio said that men with a PSA level of 10 to 20 likely would have had a PSA of greater than 20 if they did not have surgery to remove their some of their prostate, and therefore would have received more aggressive treatment.

The Fox Chase study evaluated 1,287 men with low to intermediate risk with a similar stage of disease. All had a pretreatment PSA of less than 20 and received 3D conformal radiotherapy without hormone (androgen deprivation) therapy. Of these, 143 men had a prior TURP. The median pretreatment PSA was 7.3 (range: 0.1-19.9). The number of men with PSA greater than 10 was 362 (28 percent).

Prior TURP was the common denominator among patients who had a pretreatment PSA of 10 to 19.9 who later recurred. There was no strong relationship between the surgery and recurrence for patients with a pretreatment PSA of less than 10.

As D'Ambrosio explained, "Patients with a pretreatment PSA of 10 to 19.9 were more likely to recur if they had prior TURP. This group also had other pretreatment indicators that normally would not have indicated a high-risk of recurrence." (Gleason Score of 2-6 vs. 7, Stage T1c vs. T2).

"A history of a TURP reduced the accuracy of PSA as a pretreatment indicator for recurrence. The treatment plan for men who have an intermediate PSA who have also had TURP may include a recommendation of androgen deprivation."

Other study authors include Fox Chase radiation oncologists Mark Buyyounouski, MD, Eric M. Horwitz, MD, Steven J. Feigenberg, MD, Alan Pollack, MD, PhD, and biostatistician Karen Ruth.

Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach.  For more information, call 1-888-FOX CHASE or (1-888-369-2427).

More 2005 News Releases »